^
Association details:
| Biomarker: | EGFR C797S |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Drug Class: | Notch inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Published date:
02/03/2020
Excerpt:
To test whether DBZ resensitized EGFRC797S mutant human lung adenocarcinoma cells to osimertinib in vivo, we grafted PC9GROR cells subcutaneously in mice, and 2 weeks later, we treated them with DBZ and/or osimertinib for 3 weeks…DBZ showed no effect on growth of PC9GROR cell xenografts, but importantly, tumor growth was strongly inhibited in mice treated with the osimertinib and DBZ combination...
DOI:
10.1172/JCI126896
